European Medicines Agency

The key industry bodies from across Europe have signed a letter to UK Brexit minister David Davis and EU chief Brexit negotiator Michel Barnier saying the UK must stay in the European Medicines Agency system

The European Council needs to decide in June where the EMA will relocate after Brexit. If not its “well-oiled” machinery could stall and the safety of medicines be put at risk

The competition among cities vying to replace London as home of the drug regulator is hotting up. A decision on the new location could be announced before June

A European Court of Justice ruling invalidates Guido Rasi’s appointment as head of the EMA, opening the way for further questions on the governance of the agency

It’s a virtuous circle: New approval processes put in place by the European Medicines Agency are de-risking drug development, promoting investment in early-stage biotech and meeting unmet medical needs, says Paul Morton

At the fourth time of asking, the European Medicines Agency is recommending approval of Glybera, opening up a new era in the treatment of rare diseases, and unlocking the wider potential of gene therapy

The European Medicines Agency’s thumbs-down for rare disease treatment Glybera flies in the face of Commission policy. It’s also against the wishes of the European Parliament, and the impetus DG Sanco is putting into Orphan Drugs. Worse still, it’s bad for patients and kills innovation. By Nuala Moran.

Biosimilars, e-health among areas targeted for collaboration in Science|Business panel in Washington